Artemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosis

Simple item page
dc.contributor.authorBagire, Pascal Gisenya
dc.contributor.authorOgwang, Patrick E
dc.contributor.authorLusi, Jonathan KM
dc.contributor.authorLusi, Justin Paluku
dc.contributor.authorDaddy, Nsengiyumva Bati
dc.contributor.authorKahatwa, Serge
dc.contributor.authorSerugendo, Albin
dc.contributor.authorKihemba, Kasereka
dc.date.accessioned2023-10-17T11:41:02Z
dc.date.available2023-10-17T11:41:02Z
dc.date.issued2022
dc.description.abstractIn the past few years, the number of people infected with pulmonary tuberculosis has increased.1Today, it kills thousands in Africa alone, millions worldwide and the numbers keep on increasing due to COVID-19 (WHO, 2021). Moreover, resistance to conventional anti tuberculosis recommended drugs is increasing thus rendering more and more difficult to treat this deadly disease.2 Currently, one third of the world population is infected with various forms of TB,3 and each year 2-3 million people of the world die from TB infection or its complications.4 Based on an estimate, nearly one billion people were affected by the disease between 2000 and 2020.5en_US
dc.description.sponsorshipOpalack Foundation and Ilwerliewenen_US
dc.identifier.citationBagire, P. G., Ogwang, P. E., & Lusi, J. K. M. (2022). Artemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosis. Pharm Pharmacol Int J, 10(5), 157-166.en_US
dc.identifier.urihttp://ir.must.ac.ug/handle/123456789/3184
dc.language.isoen_USen_US
dc.publisherPharmacy & Pharmacology International Journalen_US
dc.subjectPulmonary Tuberculosisen_US
dc.subjectWHOen_US
dc.subjectCOVID-19en_US
dc.subjectAfricaen_US
dc.titleArtemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosisen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Artemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosis.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Article